Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).

Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B

European urology29 Oct 2015Cited by 37 (Europe PMC)

PMID26520703DOI10.1016/j.eururo.2015.10.007PepBankPUB-26520703

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with nonmetastatic prostate cancer, time to PSA progression did not differ significantly between intermittent and continuous leuprorelin.
In plain wordsIn men with prostate cancer, time to PSA progression was similar with intermittent and continuous leuprorelin.
Peptide
Leuprolide
Outcome
No significant changeTime to PSA progression
Study
n = 701
Comparator
Continuous leuprorelin
Analysis
Primary
Outcome group
Tumor growth · Cancer
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
There were no statistically significant or clinically relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels over time, or QoL.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070302
02HumanRandomized controlled trialEfficacy outcome
In men with nonmetastatic prostate cancer, PSA progression-free survival did not differ significantly between intermittent and continuous leuprorelin.
In plain wordsIn men with prostate cancer, PSA progression-free survival was similar with intermittent and continuous leuprorelin.
Peptide
Leuprolide
Outcome
No significant changePSA progression-free survival
Study
n = 701
Comparator
Continuous leuprorelin
Analysis
Secondary
Outcome group
Tumor growth · Cancer
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
There were no statistically significant or clinically relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels over time, or QoL.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070303
03HumanRandomized controlled trialEfficacy outcome
In men with nonmetastatic prostate cancer, overall survival did not differ significantly between intermittent and continuous leuprorelin.
In plain wordsIn men with prostate cancer, overall survival was similar with intermittent and continuous leuprorelin.
Peptide
Leuprolide
Outcome
No significant changeOverall survival
Study
n = 701
Comparator
Continuous leuprorelin
Analysis
Secondary
Outcome group
Mortality · Cancer
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
There were no statistically significant or clinically relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels over time, or QoL.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070304
04HumanRandomized controlled trialEfficacy outcome
In men with nonmetastatic prostate cancer, quality of life did not differ significantly between intermittent and continuous leuprorelin.
In plain wordsIn men with prostate cancer, quality of life was similar with intermittent and continuous leuprorelin.
Peptide
Leuprolide
Outcome
No significant changeQuality of life
Study
n = 701
Comparator
Continuous leuprorelin
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
There were no statistically significant or clinically relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels over time, or QoL.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070306
05HumanRandomized controlled trialEfficacy outcome
In men with nonmetastatic prostate cancer, mean PSA levels did not differ significantly between intermittent and continuous leuprorelin.
In plain wordsIn men with prostate cancer, mean PSA levels were similar with intermittent and continuous leuprorelin.
Peptide
Leuprolide
Outcome
No significant changeMean PSA levels
Study
n = 701
Comparator
Continuous leuprorelin
Outcome group
Tumor growth · Cancer
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
There were no statistically significant or clinically relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels over time, or QoL.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070305
06HumanRandomized controlled trialSafety outcome
In men with nonmetastatic prostate cancer, adverse event counts were similar with intermittent and continuous leuprorelin.
In plain wordsIn men with prostate cancer, adverse event counts were similar with intermittent and continuous leuprorelin.
Peptide
Leuprolide
Outcome
Direction not reportedAdverse events
Study
n = 701
Comparator
Continuous leuprorelin
Outcome group
Adverse events · Whole body
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
A similar number of adverse events was observed in each group; the most common were hot flushes and hypertension.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070307
07HumanNon-randomized trialSafety outcome
In men with nonmetastatic prostate cancer, hot flushes were among the most common adverse events during leuprorelin therapy.
In plain wordsIn men with prostate cancer, hot flushes were among the most common adverse events during leuprorelin treatment.
Peptide
Leuprolide
Outcome
Direction not reportedHot flushes
Study
n = 701
Outcome group
Adverse events · Endocrine and hormones
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
A similar number of adverse events was observed in each group; the most common were hot flushes and hypertension.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070308
08HumanNon-randomized trialSafety outcome
In men with nonmetastatic prostate cancer, hypertension was among the most common adverse events during leuprorelin therapy.
In plain wordsIn men with prostate cancer, high blood pressure was among the most common adverse events during leuprorelin treatment.
Peptide
Leuprolide
Outcome
Direction not reportedHypertension
Study
n = 701
Outcome group
Blood pressure · Cardiovascular
Studied dose
22.5 mg 3-month depot · 36 monthsAs given in this study (human).
Source sentences
Summary
A similar number of adverse events was observed in each group; the most common were hot flushes and hypertension.
2 context sentences(design, population, supporting numbers)
Summary · context
A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Summary · context
Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo.
Report a problemFND-2652070309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00378690

A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD

Astellas Pharma Incn = 706Mar 2006 to Dec 2012

Prostate Cancer

Trial page ClinicalTrials.govUpdated 4 Jun 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).

Summary

Results from this study8

Registered trials1

A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD

Version history

Subjects

Publication types

MeSH terms

Keywords